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TECHNICAL NOTE
Iron removal during continuous ambulatory peritoneal dialysis
using deferoxamine
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Iron overload is a serious problem for some maintenance
hemodilaysis (MHD) patients and may be manifest by organ
dysfunction [1] and elevated serum ferritin levels [21. We had
the opportunity to study iron chelation therapy in an iron
overloaded dialysis patient during MHD and subsequently
during continuous ambulatory peritoneal dialysis (CAPD) treat-
ment and to determine the effectiveness of iron removal using
intravenous and intraperitoneal deferoxamine mesylate (Des-
ferol®, Ciba-Giegy, Summit, New Jersey).
The patient, a 37-year-old black female with sickle cell
disease and a history of multiple blood transfusions, presented
with endstage renal disease in 1975. The first 3 years of MHD
therapy were marked by congestive heart failure, progressive
hepatomegaly with mildly abnormal liver chemistries, and
symptomatic anemia for which she received over 100 blood
transfusions. In 1978, her physical exam was remarkable for a
14-cm firm nodular liver. Her hematocrit was 16%, serum
ferritin 3500 ng/ml, BUN 62 mg/dl, creatinine 10.8 mg/dl,
alkaline phosphatase 294 U/liter, and gamma glutamyltransfer-
ase 112 U/liter. A bone marrow aspirate had 4+ staining for
iron, A liver biopsy was performed which demonstrated pen-
portal and sinusoidal fibrosis. The hepatic iron concentration
was 2666 tg/d1 wet weight (normal mean value, 6 g/100 mg wet
weight) (courtesy of Dr. Corwin Q. Edwards, University of
Utah). Between 1978 and 1980 she received intravenous defer-
oxamine chelation therapy during MHD. In 1980 she underwent
cadavenic transplantation but rejected the kidney within 2
months. She then began CAPD. Evidence of iron overload
persisted with a serum ferritin of 800 ng/ml.
Methods and Results. Iron concentrations in dialysate were
determined either on a Technicon Autoanalyzer II (Technicon
Instruments Corporation, Tarrytown, New York) according to
an adaptation of the method of Parker et al [31 and Singh [4], or
on an IL Model 751 Atomic Absorption Spectrophotometer
(Instrumentation Laboratory, Inc., Analytical Instrument Div i-
sion, Wilmington, Massachusetts). Comparison of the atomic
absorption technique (x) with the Autoanalyzer method (y) on
40 CAPD fluid samples yielded the following linear regression
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equation: y = 0.939x — 0.59 mg/dl, r = 0.996. Deferoxamine in
dialysate was measured by a modification of the method of
Meyer-Brunot and Keberle [51 using the optical absorbance of
the ferric deferoxamine complex in 5% trichloroacetic acid at
430 nm to assay for the compound. The optical absorbance was
found to be directly proportional to the concentration of ferric
deferoxamine in solution. The procedure is not suitable for the
measurement of deferoxamine in serum due to the presence of
non-specific absorbance.
In 1978, while on MHD using a C-DAK 1.8 Hollow Fiber
Dialyzer(Cordis-Dow Co., Miami, Florida), the optimal dosage
of intravenous deferoxamine chelation therapy was determined
to be 1.5 g per dialysis treatment. Smaller doses removed less
iron, while larger doses did not improve iron removal. The
deferoxamine was infused into the venous return from the
dialyzer in 250 cc of normal saline during the first 2 hr of a 4-hr
dialysis. Iron removal was calculated as the product of the
concentration difference across the dialyzer (at 0, 1, 2 and 4 hr)
and the effluent volume of dialysate. There was no iron detect-
able in baseline dialysate samples.
When the patient began on CAPD in 1980, iron removal was
evaluated under two circumstances: (1) during intravenous
deferoxamine administration (1.5 g given three times a week),
and (2) during intraperitoneal deferoxamine administration (250
mg/liter): (a) to each exchange every day for 7 days (1250 mg of
deferoxamine per day); (b) to each exchange every other day
for 7 days (1250mg of deferoxamine every other day); and (c) to
the first, third and fifth exchanges every day for 7 days (750 mg
of deferoxamine per day). The small peritoneal capacity of this
patient necessitated five 1-liter exchanges of Dianeal® (Tra-
venol Laboratories, Inc., Deerfield, Illinois), 1.5% dextrose
alternating with 4.5% dextrose solutions. Deferoxamine was
given intraperitoneally by direct addition to the dialysis bags
(250 mg/liter of dialysate). Spent peritoneal dialysate was
collected for 7 days prior to, for 7 days during, and for 7 days
postchelation treatment to establish steady-state conditions.
Daily iron removal was calculated as the sum of the products of
the measured volume of dialysis effluents times their iron
concentrations. There was no iron detectable in baseline perito-
neal dialysate effluent. There were no adverse effects of defer-
oxamine administration. Peritoneal clearances of creatinine
were unchanged by deferoxamine usage. Informed consent was
obtained prior to each phase of the study.
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Table 2. Intraperitoneal deferoxamine administration
Deferoxamine dosage
Mean steady state iron removed
Per day Per week
1250 mg/day 14.2 0.3 mga(N = Il) 99.4 mg(N = 2)
750 mg/day 11.3 0.8mg (N = 6) 73 mg
1250 mg/alternate days 5.7 0.5 mg (N = 7) 39.6 mg
Values are expressed as SEM.
Day
Fig. 1. A comparison of the concentrations of deferoxamine bound to
iron and unbound deferoxamine in dialysate outflow is shown for 3
separate days. Values are expressed as SEM.
Table 1. Intravenous deferoxamine administration
Dialysis therapy Iron removed
MHD 16.5 1.7 mg per dialysis (N = 6)
1500 mg iv. 3x per week 49.6 2.9 mg/week (N = 2)
CAPD 12.56 0.9 mg/day (N = 5)
1500 mg i.v. 3x per week 78.0 mg/weeks
The lack of easily available vascular access sites prohibited addi-
tional intravenous administration while on CAPD. Values are expressed
as SEM.
Measurements of deferoxamine in dialysate effluent were
conducted to determine systemic deferoxamine absorption and
iron removal as iron bound to deferoxamine. Figure 1 displays
the amounts of iron bound to deferoxamine and of unbound
deferoxamine that were present in peritoneal dialysate effluent
during deferoxamine administration. On the average, the perito-
neal dialysate outflow contained 45% of the starting deferoxa-
mine so that the calculated parenteral load of the compound
was 55% of the total amount instilled into the peritoneal cavity.
On the 3 days shown there was substantial excess of free
(unbound) deferoxamine.
Iron removal with intravenous deferoxamine administration
during MHD averaged 16.5 1.7 mg (± SEM) of iron/dialysis (N
= 6), or 49.6 2.9 mg of iron/week (N = 2) (Table 1).
Intravenous deferoxamine during CAPD, using the same proto-
col, removed 12.6 0.9 mg of iron/day (N = 5 mean steady
state days) or 78.0 mg iron removed per week (Table 2). Iron
removal during intraperitoneal deferoxamine is shown in Table
2. Intraperitoneal administration of deferoxamine: (1)to each of
five exchanges per day for 7 consecutive days removed 14.2
0.3 mg/day of iron (N = 11 mean steady state days) or 99.4
mg/week (N = 2); (2) to each of five exchanges on an every
other day basis removed 5.7 0.5 mg/day of iron (N = 7 mean
steady state days) or 39.6 mg/week, (3) to the first, third, and
fifth exchanges every day removed 11.3 0.8 mg/day of iron (N
= 6 mean steady state days) or 73 mg/week.
Discussion
These acute studies indicate that iron can be removed simply
and effectively during CAPD, that iron removal rates exceeding
those during MHD can be achieved during CAPD, and that
significant absorption of deferoxamine into the serum occurs
with IP deferoxamine administration. Assuming a relatively
constant response to daily intraperitoneal deferoxamine, 5.2 g
of iron could be removed per year during CAPD, whereas 1500
mg of intravenous deferoxamine given during hemodialysis with
a C-DAK 1.8 dialyzer would remove only 2.6 g of iron per year.
When identical intravenous dosage schedules were compared,
chelation therapy was more efficient during CAPD than during
MHD. There are two explanations for these observations: (1)
deferoxamine and iron from a soluble complex with a molecular
weight of 617, a weight in the "middle molecule" range, known
to be cleared more efficiently during CAPD than MHD [6]; (2)
slow continuous parenteral or subcutaneous deferoxamine ther-
apy is a more effective means of iron removal than bolus
intravenous administration [71.
The measurements of free and iron-containing deferoxamine
in dialysis fluid provide insight into the events that produce iron
loss following the instillation of deferoxamine into the peritone-
al cavity. Since the inflow concentration of deferoxamine was
0.25 mg/mI, the substantially reduced concentrations of defer-
oxamine in the outflow dialysate indicate systemic absorption
of deferoxamine. We presume that this absorption leads to the
formation of an iron complex indistinguishable from that follow-
ing parenteral administration of the drug. Subsequently, the
iron complex diffuses across the peritoneal surface down its
concentration gradient into the peritoneal fluid and then is
removed from the body.
In the course of these studies intravenous deferoxamine (1500
mg 3 times a week) was given during MHD without interruption
for 2 years, 1978 to 1979. The longest period of continuous
intraperitoneal administration of deferoxamine (1250 mg/day)
was for 3 months in 1980. No toxicity was apparent. The only
toxicity of note in any long-term studies on deferoxamine has
been the development of cataracts [8]. This toxicity is dose-
related and appears to be a function of peak serum levels of the
drug, as may occur with bolus parenteral administration. Intra-
peritoneal administration during CAPD allows for significantly
smaller amounts of the drug to be given at any particular time.
Nevertheless, longer term studies will be necessary, along with
plasma measurements of deferoxamine or its metabolites, to
exclude accumulation and toxicity in patients with ESRD.
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